Adaptive randomization of neratinib in early breast cancer

New England Journal of Medicine

Volumn 375, Issue 1, 2016, Pages 11-22

  Park, John W ^a   Liu, Minetta C ^g   Yee, Douglas ^h   Yau, Christina ^a,c   Van't Veer, Laura J ^a   Symmans, W Fraser ^j   Paoloni, Melissa ^b   Perlmutter, Jane ^m   Hylton, Nola M ^a   Hogarth, Michael ^d   DeMichele, Angela ⁿ   Buxton, Meredith B ^a   Chien, A Jo ^a   Wallace, Anne M ^e   Boughey, Judy C ⁱ   Haddad, Tufia C ^h   Chui, Stephen Y ^o   Kemmer, Kathleen A ^o   Kaplan, Henry G ^p   Isaacs, Claudine ^g   Nanda, Rita ^q   Tripathy, Debasish ^f   Albain, Kathy S ^r   Edmiston, Kirsten K ^s   Elias, Anthony D ^t   Northfelt, Donald W ^u   Pusztai, Lajos ^j   Moulder, Stacy L ^j   Lang, Julie E ^v   Viscusi, Rebecca K ^v   Euhus, David M ^k   Haley, Barbara B ^k   Khan, Qamar J ^w   Wood, William C ^x   Melisko, Michelle ^a   Schwab, Richard ^e   Helsten, Teresa ^e   Lyandres, Julia ^a   Davis, Sarah E ^a   Hirst, Gillian L ^a   Sanil, Ashish ^l   Esserman, Laura J ^a   Berry, Donald A ^j,l   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Quantum Leap Healthcare Collaborative   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l BERRY CONSULTANTS   (United States)

^m Gemini Group   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p SWEDISH MEDICAL CENTER   (United States)

^q UNIVERSITY OF CHICAGO   (United States)

^r LOYOLA UNIVERSITY CHICAGO   (United States)

^s INOVA FAIRFAX HOSPITAL   (United States)

^t UNIVERSITY OF DENVER   (United States)

^u MAYO CLINIC   (United States)

^v UNIVERSITY OF ARIZONA   (United States)

^w UNIVERSITY OF KANSAS   (United States)

^x EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; NERATINIB; PACLITAXEL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PROGESTERONE RECEPTOR; QUINOLINE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BAYES THEOREM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CONFERENCE PAPER; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; FEBRILE NEUTROPENIA; FEMALE; HORMONE RECEPTOR NEGATIVE BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; BREAST NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; NEOADJUVANT THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; QUINOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRASTUZUMAB;

EID: 84978076672     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1513750     Document Type: Conference Paper

References (34)

1. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2012; 9: 199-207.
2. Berry DA. The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015; 9: 951-9.
3. Rugo H, Olopade O, DeMichele A, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL. Cancer Res 2013; 73: Suppl. abstract (http://cancerres.aacrjournals.org/content/73/24-Supplement/S5-02.abstract).
4. Tripathy D, Chien AJ, Hylton N, et al. Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: graduation results from the I-SPY 2 Trial. J Clin Oncol 2015; 33: Suppl. abstract (http://meetinglibrary.asco.org/content/150770-156).
5. Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014; 40: 259-70.
6. Chow LW, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer 2013; 108: 1985-93.
7. Sanchez-Martin M, Pandiella A. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. Int J Cancer 2012; 131: 244-52.
8. Mullooly M, Conklin D, McGowan PM, et al. Neratinib to inhibit the growth of triple-negative breast cancer cells. J Clin Oncol 2015; 33: Suppl. abstract (http://meetinglibrary.asco.org/content/153463-156).
9. Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 2015; 7: 147-62.
10. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97-100.
11. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-72.
12. Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib- carboplatin treatment in breast cancer. N Engl J Med 2016; 375:23-34.
13. Viale G, Slaets L, Bogaerts J, et al. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol 2014; 25: 816-23.
14. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006; 5: 27-36.
15. Piccart M, van 't Veer L, Slaets L, et al. Primary analysis of the EORTC 10041/BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (Mamma-Print) combined with common clinicalpathological criteria for section of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. Presented at the American Association for Cancer Research Annual Meeting, New Orleans, April 18, 2016.
16. ClinicalTrials.gov. I-SPY 2 trial: neoadjuvant and personalized adaptive novel agents to treat breast cancer. December 2015 (https://clinicaltrials.gov/show/NCT01042379).
17. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 1.2016. J Natl Compr Canc Netw 2015; 13: 1475-85.
18. Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7: 278-88.
19. Roepman P, Horlings HM, Krijgsman O, et al. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 2009; 15: 7003-11.
20. Wolf DM, Daemen A, Yau C, et al. MammaPrint ultra-high risk score is associated with response to neoadjuvant chemotherapy in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Cancer Res 2013; 73: 24 Suppl. abstract (http://cancerres.aacrjournals.org/content/73/24-Supplement/P1-08-01?cited-by= yes&legid=canres;73/24-Supplement/P1-08-01).
21. Chan A, Delaloge S, Holmes FA, et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). J Clin Oncol 2015; 33: Suppl. abstract (http://meetinglibrary.asco.org/content/149972-156).
22. Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol 2015; 33: 1574-83.
23. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014; 32: Suppl. abstract (http://meetinglibrary.asco.org/content/128258-144).
24. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-40.
25. Bria E, Carbognin L, Furlanetto J, et al. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: sensitivity analysis of randomized trials. Cancer Treat Rev 2014; 40: 847-56.
26. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012; 30: 3242-9.
27. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-22.
28. Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2014; 32: 3626-33.
29. Gandhi L, Bahleda R, Tolaney SM, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014; 32: 68-75.
30. Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol 2013; 72: 1205-12.
31. Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011; 306: 2608-9.
32. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438-41.
33. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
34. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278-84.